PACIFIC-Stroke: Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke – an international, randomised, double-blind, placebo-controlled, phase 2b trial

The Lancet

A Shoamanesh, H Mundi, EE Smith, J Masjuan, I Milanov, T Hirano, A Agafina, B Campbell, V Caso, JL Mas, Dong, P Turcani, H Christensen, JM Ferro, R Veltkamp, R Mikulik, GM De Marchis, T Robinson, R Lemmens, A Stepien, S Greisenegger, R Roine, L Csiba, P Khatri, J Coutinho, AG Lindgren, AM Demchuk, P Colorado, B Kirsch, C Neumann, L Heenan, L Xu, SJ Connolly, RG Hart

September 2022

Read More

INVICTUS: Rivaroxaban in rheumatic heart disease–associated atrial fibrillation

The New England Journal of Medicine (NEJM)

SJ Connolly, G Karthikeyan, M Ntsekhe, A Haileamlak, A El Sayed, A El Ghamrawy, A Damasceno, A Avezum, AML Dans, B Gitura, D Hu, ER Kamanzi, F Maklady, G Fana, JA Gonzalez-Hermosillo, J Musuku, K Kazmi, L Zuhlke, L Gondwe, C Ma, M Paniagua, OS Ogah, OJ Molef-Baikai, P Lwabi, P Chillo, SK Sharma, TTJ Cabral, WM Tarhuni, A Benz, M van Eikels, A Krol, D Pattath, K Balasubramanian, S Rangarajan, C Ramasundarahettige, B Mayosi, S Yusuf

August 2022

Read More

Back To Top